The role of clofarabine in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 688-698

  Ghanem, Hady ^a   Kantarjian, Hagop ^a   Ohanian, Maro ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clofarabine; Hematologic malignancies; Nucleoside analog; Solid tumors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; TEMSIROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CYTOTOXICITY; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADENINE NUCLEOTIDES; AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84879363702     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.726722     Document Type: Review

References (50)

1. Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2 ' -deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 23-29.
2. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2 ' -arabino-fluoro-2 ' -deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 2970-2974.
3. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, anovel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438-2444.
4. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847-2852.
5. Pui C H, Jeha S. C lofarabine. N at Rev Drug Discov 2 005(Suppl.): S12-S13.
6. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991; 51: 2386-2394.
7. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030-3037.
8. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly aff ecting the mitochondria. Blood 2000; 96: 3537-3543.
9. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999; 55: 515-520.
10. Parker WB, Bapat AR, Shen JX, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988; 34: 485-491.
11. Takahashi T, Kanazawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, anovel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999; 43: 233-240.
12. Waud W R, Schmid S M, Montgomery J A, et al. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000; 19: 447-460.
13. Avramis VI, Plunkett W. Metabolism of 9-beta-D-arabinosyl-2- fluoroadenine-5'-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1983; 1: 1-10.
14. Response of subcutaneous HT-29 tumor to clofarabine or CPT-11 (Final report ILEX 27). Birmingham, AL: Southern Research Institute; 2003.
15. Clofarabine investigator' s brochure, 6th ed. F inal report. San Antonio, TX: Genzyme Corp.; 2007.
16. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167-1173.
17. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003; 9: 6335-6342.
18. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
19. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48: 329-334.
20. Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985; 12: 20-30.
21. Estey E, Plunkett W, Dixon D, et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580-583.
22. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005; 55: 361-368.
23. Moufarij MA, Sampath D, Keating MJ, et al. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108: 4187-4193.
24. Foran JM, Faderl S, Wetzler M, et al. A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003; 22: Abstract 2360.
25. Racil Z, Toskova M, Dvorakova D, et al. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. Am J Hematol 2011 Oct 12. [Epub ahead of print]
26. Krawczyk J, Ansar N, Swords R, et al. Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematol Oncol 2010; 28: 118-123.
27. Faderl S, Garcia-Manero G, Jabbour E, et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012; 118: 722-728.
28. Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010; 28: 2755-2760.
29. Faderl S, Gandhi V, O' B rien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940-947.
30. Faderl S, Gandhi V, Verstovsek S, et al. Clofarabine plus cytarabine (ara-C) combination is active in newly diagnosed patients (pts) >= age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood 2004; 104(Suppl. 1): Abstract 875.
31. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
32. Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011; 16: 197-206.
33. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012; 118: 4471-4477.
34. Becker P S, Kantarjian H M, Appelbaum F R, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011; 155: 182-189.
35. Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580-3589.
36. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, et a l. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002; 68: 370-375.
37. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008; 113: 2090-2096.
38. Nazha A, Ravandi F, Kantarjian HM, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients younger than 61 years with newly diagnosed acute myeloid leukemia (AML). Blood 2011; 118(Suppl. 1): Abstract 1550.
39. Mathisen M, Kantarjian H, Faderl S, et al. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). J Clin Oncol 2012; 30(Suppl.): Abstract 6607.
40. Burnett AK, Kell WJ, Hills RK, et al. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A pilot study. Blood 2006; 108(Suppl.): Abstract 1950.
41. Foster M C, Amin C, Voorhees P M, et al. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma 2012; 53: 1331-1337.
42. Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012; 156: 205-212.
43. Kantarjian H, Ravandi F, O' Brien S, et al: Intensive chemotherapy does not benefi t most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116: 4422-4429.
44. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
45. Kantarjian H M, Erba H P, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549-555.
46. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I trial. J Clin Oncol 2012; 30: 2492-2499.
47. Martin MG, Uy GL, Procknow E, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009; 44: 13-17.
48. Farag SS, Wood LL, Schwartz JE, et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011; 25: 599-605.
49. Locke FL, Artz A, Rich E, et al. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 2010; 45: 1692-1698.
50. Buchholz S, Dammann E, Stadler M, et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012; 88: 52-60.